Navina names former Salesforce health chief Joshua Newman as CMO

Navina appoints Joshua Newman as chief medical officer

Navina announced on November 5 that it had appointed Dr. Joshua Newman as Chief Medical Officer. Newman, who spent nearly 14 years at Salesforce in senior executive roles, will lead the clinical vision and strategy of Navina’s AI-powered clinical intelligence platform.

In announcing the appointment, Navina said Newman will also oversee physician engagement, help drive implementation and adoption, and work with physicians and care teams to incorporate their feedback into the product roadmap.

Salesforce experience brings health-system and payer perspective

At Salesforce, Newman served as Senior Vice President and Chief Medical Officer and as Senior Vice President and Global General Manager of Healthcare and Life Sciences. Navina said he helped develop the company’s healthcare business and its relationships with health systems and payers.

Before joining Navina, Newman was Chief Strategy Officer at Alleviate.care, a physician-led hospice and palliative care organization. He began his career in clinical practice and later served as an assistant professor of medicine at UCLA.

Clinical and commercial responsibilities

In his new role, Newman will work with Navina’s go-to-market teams on customer relationships and support for prospects. He will also represent the company in industry discussions about artificial intelligence, population health management and clinical outcomes.

Navina describes its platform as an AI copilot that brings clinical information into physicians’ existing workflows. The company says the technology is intended to help clinicians identify care gaps, improve documentation accuracy and make treatment decisions without manually reviewing extensive medical records.

Platform scale reported by Navina

Navina says its platform has been used by more than 20,000 clinicians and care team members across over 1,300 clinics in the United States, helping support care for more than five million patient lives. These figures are company-reported and describe existing platform use rather than a newly disclosed contract or purchase order.

The appointment is part of Navina’s effort to expand adoption of the platform among U.S. healthcare organizations. A future measure of whether the appointment advances that effort would be further disclosure about implementation, adoption and measurable clinical outcomes.